Bristol Myers Q2 2026 Results Beat, Lifts 2026 Revenue Outlook
Bristol Myers reported Q2 2026 revenues of $13.0B and lifted its full-year outlook, highlighting strong growth from its portfolio of oncology, hematology, and cardiovascular medicines.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day